## Igor B Roninson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6803004/publications.pdf

Version: 2024-02-01

24978 20900 19,422 133 57 115 citations h-index g-index papers 133 133 133 21944 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. Journal of Medicinal Chemistry, 2022, 65, 3420-3433.	2.9	14
2	The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs. Cells, 2021, 10, 144.	1.8	16
3	Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types. Cancers, 2021, 13, 3155.	1.7	14
4	Identifying Cancers Impacted by CDK8/19. Cells, 2019, 8, 821.	1.8	31
5	Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay. Cells, 2019, 8, 1208.	1.8	11
6	Role of transcription-regulating kinase CDK8 in colon cancer metastasis. Oncotarget, 2019, 10, 622-623.	0.8	6
7	Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science, 2019, 363, 753-756.	6.0	330
8	Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition. Cells, 2019, 8, 1413.	1.8	33
9	Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1973-E1982.	3.3	153
10	CDK8 Selectively Promotes the Growth of Colon Cancer Metastases in the Liver by Regulating Gene Expression of TIMP3 and Matrix Metalloproteinases. Cancer Research, 2018, 78, 6594-6606.	0.4	65
11	Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. Oncogene, 2018, 37, 4792-4808.	2.6	49
12	CDK8/19 Mediator kinases potentiate induction of transcription by NFκB. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10208-10213.	3.3	89
13	Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget, 2017, 8, 12558-12575.	0.8	92
14	Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing. Nature Cell Biology, 2016, 18, 777-789.	4.6	244
15	Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. Oncotarget, 2015, 6, 13088-13104.	0.8	18
16	Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer. Current Cancer Drug Targets, 2015, 15, 739-749.	0.8	67
17	Abstract PRO8: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. , 2015, , .		1
18	Abstract 5459: Overcoming resistance to HER2-targeting drugs using CDK8 inhibitors., 2015,,.		0

#	Article	lF	Citations
19	Abstract 4879: Targeting the seed and the soil of cancers with selective small-molecule inhibitors of CDK8/19: Chemopotentiating, chemopreventive, anti-invasive and anti-metastatic activities. Cancer Research, 2014, 74, 4879-4879.	0.4	3
20	Abstract 2101: Role of CDK8 in estrogen receptor signaling in breast cancers. , 2014, , .		0
21	Abstract 5104: Identification of cancer-specific COPI inhibitors and their associated apoptotic cell death pathways. , 2014, , .		0
22	Abstract 616: Transcription-regulating kinases CDK8 and CDK19 as novel the rapeutic targets for advanced prostate cancer. , 2014, , .		0
23	Abstract 4883: CDK8: A new druggable mediator of NFκB activity. , 2014, , .		0
24	Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13799-13804.	3.3	146
25	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
26	Reactive Oxygen Species and Mitochondrial Sensitivity to Oxidative Stress Determine Induction of Cancer Cell Death by p21. Journal of Biological Chemistry, 2012, 287, 9845-9854.	1.6	77
27	Abstract 1820: CDK3: A novel tumor-selective drug target involved in AP1 activation and transcriptional damage response. Cancer Research, 2012, 72, 1820-1820.	0.4	1
28	Effects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cells. Cell Cycle, 2011, 10, 3505-3514.	1.3	31
29	Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit Â2 renders tumor cells dependent on its paralogous gene COPZ1. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12449-12454.	3.3	40
30	A subunit of coatomer protein complex offers a novel tumor-specific target through a surprising mechanism. Autophagy, 2011, 7, 1551-1552.	4.3	11
31	Abstract LB-401: The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468(â^^) triple-negative breast cancer (TNBC) cell line. , 2011, , .		5
32	Mitotic Catastrophe. , 2011, , 2345-2347.		0
33	Molecular remodeling of potassium channels in fibroblasts from centenarians: A marker of longevity?. Mechanisms of Ageing and Development, 2010, 131, 674-681.	2.2	8
34	Function-based gene identification using enzymatically generated normalized shRNA library and massive parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7377-7382.	3.3	15
35	Abstract 3022: The identification of novel senescence-associated miRNAs. , 2010, , .		0
36	A structural interpretation of the effect of GC-content on efficiency of RNA interference. BMC Bioinformatics, 2009, 10, S33.	1.2	74

#	Article	IF	Citations
37	Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro. British Journal of Cancer, 2009, 101, 1900-1908.	2.9	44
38	EXPRESSION OF SENESCENCE-ASSOCIATED GROWTH REGULATORY PROTEINS IN HUMAN PROSTATE CANCER. Journal of Urology, 2009, 181, 514-514.	0.2	0
39	Identification of single nucleotide polymorphisms in the p21 (CDKN1A) gene and correlations with longevity in the Italian population. Aging, 2009, 1, 470-480.	1.4	34
40	Repression of the SUMOâ€specific protease Senp1 induces p53â€dependent premature senescence in normal human fibroblasts. Aging Cell, 2008, 7, 609-621.	3.0	54
41	THERAPY-INDUCED SENESCENCE RESPONSE AND DIFFERENTIAL GENE EXPRESSION IN PROSTATE CANCER CELLS WITH VARIABLE METASTATIC POTENTIAL. Journal of Urology, 2008, 179, 191-192.	0.2	1
42	Regulation of Sp1 by cell cycle related proteins. Cell Cycle, 2008, 7, 2856-2867.	1.3	64
43	p21 (CDKN1A) is a Negative Regulator of p53 Stability. Cell Cycle, 2007, 6, 1467-1470.	1.3	53
44	Effect of target secondary structure on RNAi efficiency. Rna, 2007, 13, 1631-1640.	1.6	148
45	The STAT3 oncogene as a predictive marker of drug resistance. Trends in Molecular Medicine, 2007, 13, 4-11.	3.5	112
46	p21Waf1/Cip1/Sdi1 mediates retinoblastoma protein degradation. Oncogene, 2007, 26, 6954-6958.	2.6	78
47	p21 (CDKN1A) is a negative regulator of p53 stability. Cell Cycle, 2007, 6, 1468-71.	1.3	27
48	Proteomic analysis of factors released from p21-overexpressing tumour cells. Proteomics, 2006, 6, 3739-3753.	1.3	12
49	Cell Cycle Arrest Drastically Extends the Duration of Gene Silencing After Transient Expression of Short Hairpin RNA. Cell Cycle, 2006, 5, 2390-2395.	1.3	18
50	Cell Adhesion Molecule L1 Disrupts E-Cadherin-Containing Adherens Junctions and Increases Scattering and Motility of MCF7 Breast Carcinoma Cells. Cancer Research, 2006, 66, 11370-11380.	0.4	118
51	Agonist and Antagonist of Retinoic Acid Receptors Cause Similar Changes in Gene Expression and Induce Senescence-like Growth Arrest in MCF-7 Breast Carcinoma Cells. Cancer Research, 2006, 66, 8749-8761.	0.4	36
52	Src Inhibits Adriamycin-Induced Senescence and G2 Checkpoint Arrest by Blocking the Induction of p21waf1. Cancer Research, 2005, 65, 8927-8935.	0.4	55
53	Seeking favors from nature. Cancer Biology and Therapy, 2005, 4, 794-799.	1.5	1
54	Tumor Suppressor Maspin Is Up-Regulated during Keratinocyte Senescence, Exerting a Paracrine Antiangiogenic Activity. Cancer Research, 2004, 64, 2956-2961.	0.4	60

#	Article	IF	Citations
55	Induction of Transcription by p21Waf1/Cip1/Sdi1: Role of NF?B and Effect of Non-steroidal Anti-inflammatory Drugs. Cell Cycle, 2004, 3, 929-938.	1.3	27
56	Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene, 2004, 23, 2919-2933.	2.6	451
57	Induction of transcription by p21Waf1/Cip1/Sdi1: role of NFkappaB and effect of non-steroidal anti-inflammatory drugs. Cell Cycle, 2004, 3, 931-40.	1.3	10
58	Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell, 2003, 4, 41-53.	7.7	72
59	Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell, 2003, 4, 415.	7.7	2
60	Induction of senescence-associated growth inhibitors in the tumor-suppressive function of retinoids. Journal of Cellular Biochemistry, 2003, 88, 83-94.	1.2	37
61	Genetic Suppressor Elements in the Characterization and Identification of Tumor Suppressor Genes., 2003, 222, 413-436.		6
62	Tumor cell senescence in cancer treatment. Cancer Research, 2003, 63, 2705-15.	0.4	473
63	Identification of Promoter Elements Responsible for Transcriptional Inhibition of Polo-like Kinase 1 and Topoisomerase $\hat{\text{Ill}}$ Genes by p21WAF1/CIP1/SDI1. Cell Cycle, 2002, 1, 55-62.	1.3	42
64	Induction of Transcription through the p300 CRD1 Motif by p21WAF1/CIP1Is Core Promoter Specific and Cyclin Dependent Kinase Independent. Cell Cycle, 2002, 1, 332-339.	1.3	29
65	Retinoid-Induced Growth Arrest of Breast Carcinoma Cells Involves Co-Activation of Multiple Growth-Inhibitory Genes. Cancer Biology and Therapy, 2002, 1, 24-27.	1.5	63
66	Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 389-394.	3.3	272
67	Tumor senescence as a determinant of drug response in vivo. Drug Resistance Updates, 2002, 5, 204-208.	6.5	77
68	Oncogenic functions of tumour suppressor p21Waf1/Cip1/Sdi1: association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Letters, 2002, 179, 1-14.	3.2	395
69	Induction of transcription through the p300 CRD1 motif by p21WAF1/CIP1 is core promoter specific and cyclin dependent kinase independent. Cell Cycle, 2002, 1, 343-50.	1.3	14
70	P-Glycoprotein-Mediated Colchicine Resistance in Different Cell Lines Correlates with the Effects of Colchicine on P-Glycoprotein Conformationâ€. Biochemistry, 2001, 40, 4323-4331.	1.2	30
71	If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resistance Updates, 2001, 4, 303-313.	6.5	625
72	Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes and Development, 2001, 15, 2203-2208.	2.7	814

#	Article	IF	CITATIONS
73	Coordinate Changes in Drug Resistance and Drug-Induced Conformational Transitions in Altered-Function Mutants of the Multidrug Transporter P-Glycoproteinâ€. Biochemistry, 2001, 40, 4332-4339.	1.2	36
74	Analysis of MDR1 P-Glycoprotein Conformational Changes in Permeabilized Cells Using Differential Immunoreactivityâ€. Biochemistry, 2001, 40, 4312-4322.	1.2	61
75	p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene, 2000, 19, 2165-2170.	2.6	171
76	Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: Implications for carcinogenesis, senescence, and age-related diseases. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4291-4296.	3.3	407
77	Functional Approaches to Gene Isolation in Mammalian Cells. Science, 1999, 285, 299a-299.	6.0	7
78	Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells. Oncogene, 1999, 18, 377-384.	2.6	143
79	Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene, 1999, 18, 4808-4818.	2.6	352
80	A Combination of Genetic Suppressor Elements Produces Resistance to Drugs Inhibiting DNA Replication. Somatic Cell and Molecular Genetics, 1999, 25, 9-26.	0.7	19
81	Alteration of Skin Protein Kinase C α Protein and mRNA Levels during Induced Mouse Hair Growth. Journal of Dermatology, 1999, 26, 203-209.	0.6	4
82	Internal Ribosomal Entry Site-Containing Retroviral Vectors with Green Fluorescent Protein and Drug Resistance Markers. Human Gene Therapy, 1998, 9, 1233-1236.	1.4	31
83	Drug-stimulated Nucleotide Trapping in the Human Multidrug Transporter MDR1. Journal of Biological Chemistry, 1998, 273, 10132-10138.	1.6	82
84	[16] Isolation of altered-function mutants and genetic suppressor elements of multidrug transporter P-glycoprotein by expression selection from retroviral libraries. Methods in Enzymology, 1998, 292, 225-248.	0.4	3
85	60-Hz Electric Fields Inhibit Protein Kinase C Activity and Multidrug Resistance Gene (MDR1) Up-Regulation. Radiation Research, 1997, 147, 369.	0.7	16
86	Evaluation of newer prognostic markers for adult soft tissue sarcomas Journal of Clinical Oncology, 1997, 15, 3249-3257.	0.8	80
87	P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 12908-12913.	3.3	174
88	Applications of green fluorescent protein as a marker of retroviral vectors. Somatic Cell and Molecular Genetics, 1997, 23, 325-340.	0.7	27
89	Adriamycin activates c-jun N-terminal kinase in human leukemia cells: a relevance to apoptosis. Cancer Letters, 1996, 107, 73-81.	3.2	108
90	Inducible retroviral vectors regulated by lac repressor in mammalian cells. Gene, 1996, 183, 137-142.	1.0	20

#	Article	IF	CITATIONS
91	P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 1238-1242.	3.3	102
92	Effects of infection rate and selection pressure on gene expression from an internal promoter of a double gene retroviral vector. Somatic Cell and Molecular Genetics, 1996, 22, 291-309.	0.7	17
93	Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate., 1996, 65, 613-619.		68
94	Inhibition of cytarabine-inducedMDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function., 1996, 68, 245-250.		35
95	Altered Drug-stimulated ATPase Activity in Mutants of the Human Multidrug Resistance Protein. Journal of Biological Chemistry, 1996, 271, 1877-1883.	1.6	143
96	Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate., 1996, 65, 613.		1
97	Human (MDR1) and Mouse (mdr1,mdr3) P-glycoproteins Can Be Distinguished by Their Respective Drug Resistance Profiles and Sensitivity to Modulators. Biochemistry, 1995, 34, 32-39.	1.2	108
98	Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3744-3748.	3.3	130
99	Variable effects of sodium butyrate on the expression and function of the MDR 1 (P-glycoprotein) gene in colon carcinoma cell lines. International Journal of Cancer, 1993, 55, 297-302.	2.3	33
100	Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. International Journal of Cancer, 1993, 55, 478-484.	2.3	68
101	MDR-1 Expression in Metastatic Malignant Melanoma. Journal of Surgical Research, 1993, 54, 621-624.	0.8	17
102	Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3231-3235.	3.3	127
103	Isolation of dominant negative mutants and inhibitory antisense RNA sequences by expression selection of random DNA fragments. Nucleic Acids Research, 1992, 20, 711-717.	6.5	60
104	Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 5824-5828.	3.3	290
105	The role of the MDR1 (p-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochemical Pharmacology, 1992, 43, 95-102.	2.0	166
106	From amplification to function: the case of the MDR1 gene. Mutation Research - Reviews in Genetic Toxicology, 1992, 276, 151-161.	3.0	47
107	Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 1991, 66, 85-94.	13.5	926
108	Correlation between amount of virus with altered nucleotide sequence and the monkey test for acceptability of oral poliovirus vaccine Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 199-203.	3.3	153

#	Article	IF	Citations
109	Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 7386-7390.	3.3	67
110	Quantitative Estimation of MDR1 mRNA Levels by Polymerase Chain Reaction., 1991,, 319-333.		12
111	Isolation and Characterization of the Human MDR (P-Glycoprotein) Genes., 1991,, 91-106.		13
112	Structure and Evolution of P-Glycoproteins. , 1991, , 189-211.		8
113	Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185Val-185 substitution in P-glycoprotein Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 7225-7229.	3.3	157
114	Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 7160-7164.	3.3	692
115	An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell, 1988, 53, 519-529.	13.5	437
116	mRNA phenotyping by enzymatic amplification of randomly primed cDNA. Nucleic Acids Research, 1988, 16, 10366-10366.	6.5	137
117	Analysis of gene amplification in human tumor cell lines Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 6846-6850.	3.3	39
118	Expression, Amplification, and Transfer of DNA Sequences Associated with Multidrug Resistance. , 1988, , 243-257.		2
119	[25] Use of in-gel DNA renaturation for detection and cloning of amplified genes. Methods in Enzymology, 1987, 151, 332-371.	0.4	14
120	70 Highly sensitive procedure for detection of amplified DNA. Cancer Genetics and Cytogenetics, 1987, 28, 46.	1.0	1
121	Localization of the human multiple drug resistance gene, MDR1, to 7q21.1. Human Genetics, 1987, 77, 142-144.	1.8	156
122	The mdrl gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochemical and Biophysical Research Communications, 1986, 141, 956-962.	1.0	389
123	Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science, 1986, 232, 643-645.	6.0	600
124	Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 1986, 47, 381-389.	13.5	1,902
125	Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 337-341.	3.3	215
126	Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 4538-4542.	3.3	636

#	Article	IF	CITATIONS
127	Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somatic Cell and Molecular Genetics, 1986, 12, 415-420.	0.7	75
128	Detection of amplified sequences in mammalian DNA by in-gel renaturation and SINE hybridization. Somatic Cell and Molecular Genetics, 1986, 12, 611-623.	0.7	5
129	Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells. Nature, 1984, 309, 626-628.	13.7	326
130	Detection and mapping of homologous, repeated and amplified DNA sequences by DNA renaturation in agarose gets. Nucleic Acids Research, 1983, 11, 5413-5431.	6.5	128
131	Gene evolution in the chicken $\hat{I}^2$ -globin cluster. Cell, 1982, 28, 515-521.	13.5	28
132	Structural characterization of the adenovirus 18 inverted terminal repetition. Virology, 1982, 121, 230-239.	1.1	15
133	Studies on the nature of the linkage between the terminal protein and the adenovirus DNA. Biochemical and Biophysical Research Communications, 1980, 94, 398-405.	1.0	16